KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Common Equity (2016 - 2025)

NovoCure (NVCR) has disclosed Common Equity for 12 consecutive years, with $340.5 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 5.47% to $340.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $340.5 million through Dec 2025, down 5.47% year-over-year, with the annual reading at $340.5 million for FY2025, 5.47% down from the prior year.
  • Common Equity hit $340.5 million in Q4 2025 for NovoCure, roughly flat from $341.3 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $445.4 million in Q3 2022 to a low of $340.5 million in Q4 2025.
  • Historically, Common Equity has averaged $389.8 million across 5 years, with a median of $382.9 million in 2021.
  • Biggest five-year swings in Common Equity: skyrocketed 53.81% in 2021 and later dropped 17.83% in 2023.
  • Year by year, Common Equity stood at $410.5 million in 2021, then increased by 7.47% to $441.2 million in 2022, then dropped by 17.83% to $362.5 million in 2023, then fell by 0.64% to $360.2 million in 2024, then decreased by 5.47% to $340.5 million in 2025.
  • Business Quant data shows Common Equity for NVCR at $340.5 million in Q4 2025, $341.3 million in Q3 2025, and $349.4 million in Q2 2025.